Nerdwallet Inc vs Revvity Inc — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $625.17M), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 20.7× Nerdwallet Inc's market cap, and Revvity Inc pays a 0.24% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | RVTY | |
|---|---|---|
Market Cap | $625.17M | $12.91B |
Sector | Financials | Technology |
52-Week High | $15.93 | $117.75 |
52-Week Low | $7.58 | $82.26 |
Enterprise Value | $539.47M | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.
NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Trailing returns across standard periods
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →